gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Cyclin O

This gene, which has a previous symbol of UNG2, was erroneously identified as a uracil DNA glycosylase in PubMed ID: 2001396. A later publication, PubMed ID: 8419333, identified this gene's product as a cyclin protein family member. The UNG2 term is also used as a specific protein isoform name for the UNG gene (GeneID 7374), so confusion exists in the scientific literature and in some databases for these two genes.[provided by RefSeq, Nov 2010] (from NCBI)
Sponsored links
Top mentioned proteins: CAN, HAD, Methylguanine-DNA Methyltransferase, p53, OUT
Papers on CCNU
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
French et al., Rotterdam, Netherlands. In Cancer Res, Feb 2016
UNASSIGNED: The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM).
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
Xiong et al., Shanghai, China. In Cell Rep, Jan 2016
Chemotherapy of a combination of DNA alkylating agents, procarbazine and lomustine (CCNU), and a microtubule poison, vincristine, offers a significant benefit to a subset of glioma patients.
Downregulation of Id2 increases chemosensitivity of glioma.
Yu et al., Beijing, China. In Tumour Biol, Jun 2015
The changes in response to antitumor agents Me-CCNU, VM26, and TMZ were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
What is New in the Management of Epilepsy in Gliomas?
Soffietti et al., Torino, Italy. In Curr Treat Options Neurol, Jun 2015
Radiotherapy and chemotherapy with alkylating agents (procarbazine, CCNU, vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with pharmacoresistant epilepsy.
Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Okumura et al., Japan. In Res Vet Sci, Apr 2015
The results showed that in HS cells with lomustine (CCNU) resistance, YM155 treatment suppressed both the cell-growth potential and cell resistance to CCNU, which essentially increases the chemotherapy efficacy in the murine models.
Molecular signalling pathways in canine gliomas.
Dickinson et al., College Station, United States. In Vet Comp Oncol, Apr 2015
Protein expression was defined in three canine astrocytic glioma cell lines treated with CCNU, temozolamide or CPT-11 and was further evaluated in 22 spontaneous gliomas including high and low grade astrocytomas, high grade oligodendrogliomas and mixed oligoastrocytomas.
Influence of the Expression Level of O6-Alkylguanine-DNA Alkyltransferase on the Formation of DNA Interstrand Crosslinks Induced by Chloroethylnitrosoureas in Cells: A Quantitation Using High-Performance Liquid Chromatography-Mass Spectrometry.
Zhong et al., Beijing, China. In Plos One, 2014
The results indicate that nimustine (ACNU) induced more dG-dC crosslinks in L1210 leukemia cells than those induced by carmustine (BCNU), lomustine (CCNU) and fotemustine (FTMS).
Predictive biomarkers in adult gliomas: the present and the future.
Ducray et al., Lyon, France. In Curr Opin Oncol, 2013
RECENT FINDINGS: The long-term results of the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer trials in anaplastic oligodendroglial glioma have shown that the 1p/19q codeletion predicts an overall survival benefit from early PCV (procarbazine CCNU vincristine) chemotherapy.
UNG shapes the specificity of AID-induced somatic hypermutation.
Ramiro et al., Madrid, Spain. In J Exp Med, 2012
Results show uracil-N-glycosylase (UNG) as a new molecular layer that shapes the specificity of activation-induced deaminase (AID)-induced mutations and may provide new insights into the role of AID in cancer development.
Uracil DNA N-glycosylase promotes assembly of human centromere protein A.
Wang et al., San Diego, United States. In Plos One, 2010
UNG2 colocalizes with CENP-A and H2AX phosphorylation at centromeres in normally cycling cells.
HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation.
Gronenborn et al., Pittsburgh, United States. In J Biol Chem, 2010
UNG specifically interacts with Vpr forming a heterotrimeric complex with DCAF1.
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Weller et al., Tübingen, Germany. In J Clin Oncol, 2010
PATIENTS AND METHODS: Patients (N = 318) were randomly assigned 2:1:1 (A:B1:B2) to receive conventional radiotherapy (arm A); procarbazine, lomustine (CCNU), and vincristine (PCV; arm B1); or temozolomide (arm B2) at diagnosis.
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
Herrlinger et al., Bonn, Germany. In J Clin Oncol, 2009
PURPOSE: To evaluate long-term survival in a prospective series of patients newly diagnosed with glioblastoma and treated with a combination of lomustine (CCNU), temozolomide (TMZ), and radiotherapy.
Identification of a novel cyclin required for the intrinsic apoptosis pathway in lymphoid cells.
Gil-Gómez et al., Barcelona, Spain. In Cell Death Differ, 2009
Cyclin O activation correlates with apoptosis induction in vivo.
Procarbazine--a traditional drug in the treatment of malignant gliomas.
Hau et al., Regensburg, Germany. In Curr Med Chem, 2007
The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas.
Advances in the biology and treatment of oligodendrogliomas.
van den Bent, Rotterdam, Netherlands. In Curr Opin Neurol, 2004
It is clear that temozolomide is a good alternative to procarbazine, CCNU and vincristine (PCV) chemotherapy, in particular, because it is better tolerated.
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Jenkins et al., Rochester, United States. In J Clin Oncol, 2003
Because procarbazine, lomustine (CCNU), and vincristine (PCV) is active in patients with recurrent LGO/LGOA, we hypothesized that it would be beneficial as primary therapy.
NO-mediated chemoresistance in C6 glioma cells.
Hsu et al., Saint Louis, United States. In Ann N Y Acad Sci, 2002
We note that increased NO synthesis by cytokine exposure or iNOS overexpression neutralized the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), but not cisplatin, in rat C6 glioma cells.
[Recent advance in chemotherapy for advanced colorectal cancer].
Aiba, Japan. In Gan To Kagaku Ryoho, 1996
While 5-fluorouracil (5-FU) is a key drug for more than three decades, many a combination chemotherapy with 5-FU and other drugs such as methyl-CCNU, vincristine, streptozocin, mitomycin C and so on has been studied extensively only to show no significant improvement compared with monotherapy with 5-FU.
Cell cycle regulation of a human cyclin-like gene encoding uracil-DNA glycosylase.
Caradonna et al., Stratford, United States. In J Biol Chem, 1993
This publication corrected the mistaken attribution of uracil DNA glycosylase activity to this gene.
share on facebooktweetadd +1mail to friends